 |
> 1996 Publications
1. Prognostic
value of BHCG and local tumor invasion in stage I seminoma of
the testis.
Schwartz BF, Auman R, Peretsman SJ, Moul JW, Deshon GE, Hernandez
J, Rozanski TA, Thrasher JB:
J. Surg. Oncol, 61:131-133, 1996. |
2. Protein
expression of p53, bcl-2 and Ki-67 (MIBI) as prognostic biomarkers
in patients with surgically treated, clinically localized prostate
cancer.
Moul, JW, Bettencourt, MC, Sesterhenn, IA, Mostofi, FK, McLeod,
DG, Srivastava, S, and Bauer, JJ:
Surgery, 120:159-167, 1996. |
3. Management
of Prostate Cancer for Primary Care: Epidemiology and Screening.
Moul JW:
Fed Prac (Supplement) 1996, pp 3-8. |
4. Cathepsin-D
and Epidermal Growth Factor Receptor (EGFR), immunohistochemistry
does not predict recurrence of prostate cancer in patients undergoing
radical prostatectomy.
Moul JW, MayGarden SJ, Ware JL, Mohler JL, Maher PD, Schenkman
NS, and Ho CK:
J Urol, 155:982-985, 1996. |
5. Prognostic
factors in low-stage non-seminomatous testicular cancer.
Moul JW, Heidenreich A:
Oncology, 10 (9): 1359-1374, 1996. |
6. Black
race is an adverse prognostic factor for prostate cancer recurrence
following radical prostatectomy in an equal-access health care
system.
Moul JW, Douglas TH, McCarthy WF, and McLeod DG:
J Urol 155:1667-1673, 1996. |
7. Prospective
use of free PSA to avoid repeat prostate biopsies in men with
elevated total PSA.
Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW:
Urology, 48(Suppl.) S76, 1996. |
8. Prospective
use of free PSA to avoid repeat prostate biopsies in men with
elevated total PSA.
Morgan TO, McLeod DG, Leifer ES, Moul JW, Murphy GP:
The Prostate (Suppl. 7):58-63, 1996. |
9. Age-specific
reference ranges for prostate specific antigen-based detection
of prostate cancer in African American men.
Morgan TO, Jacobsen SJ, McCarthy WF, McLeod DG and Moul JW:
New England Journal of Medicine, 335:304-310, 1996. |
10. Renal
milk of calcium: contraindication to extracorporeal shock wave
lithotripsy.
Heidenreich A, Vorreuther R, Krug B, Moul JW, Engelmann UH.
Techniques in Urology, 2:121-125, 1996. |
11. The
role of the p53 tumor suppressor gene in prostate cancer: a possible
biomarker?
Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, and Srivastava S:
Urology 48:971-979, 1996. |
12. Teleconferencing
as a method of educating men about managing advanced prostate
cancer and pain.
Glajchen M, and Moul JW:
J Psychosocial Oncol, 14 (2):73-87, 1996. |
13. Patient
selection for experimental adjuvant therapy after radical prostatectomy
(letter).
Douglas TH, McCarthy WF, McLeod DG, and Moul JW:
Urology, 47:284-285, 1996. |
14. Ki-67
expression is a prognostic marker of prostate cancer recurrence
after radical prostatectomy.
Bettencourt M, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG,
and Moul JW:
J Urol, 156:1064-1068, 1996. |
15. Elevated
levels of apoptosis regulator proteins p53 and bcl-2 are independent
prognostic biomarkers in surgically treated clinically localized
prostate cancer patients.
Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S,
and Moul JW:
J Urol, 156: 1511-1516, 1996. |
16. Review
of current detection and treatment options.
Bauer JJ, McLeod DG, and Moul JW:
Prostate cancer: Fed Prac Oct, pp 72-90, 1996. |
17. Prostate
cancer: Diagnosis, treatment and experience at one tertiary military
medical center, 1989 and 1994.
Bauer JJ, McLeod DG, and Moul JW:
Milit Med, 161:646-653,1996. |
 Back
to Top |
|
